Cellibre
San Diego, US · Founded 2017 · Delaware corporation · 8 known investors
Cellibre engineers biological manufacturing by programming cells to produce industrial products through fermentation rather than traditional chemical synthesis. The company serves manufacturers seeking sustainable, cost-effective production of chemicals, materials, and other goods using cellular factories.
Founders & leadership
Cellibre was founded in 2017 by Ben Chiarelli.
Investors · 8
Beresford VenturesOrlando
Dellin InvestmentsPhiladelphia
Delta Emerald Ventures
JourneyOne VenturesBouldervia Helene Servillon · inferred
Merida Capital HoldingsRye
Flatiron Venture PartnersreportedNew York
Also in the syndicate · 2
Entourage Effect CapitalL2V
Reported raises · per SEC filings
Form D private placements$20.8M disclosed across 3 rounds · 2019–2024
▶$6.7MraisedOct 2024 · 31 investors · BiotechnologyRule 506(b)
▶$6.7MraisedOct 2024 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicky CaiazzaExecutive Officer, Director
- Scott ZingheimExecutive Officer, Director
- Spiros KambourakisExecutive Officer, Director
- Benjamin ChiarelliExecutive Officer, Director
- Offering amount
- $23.2M
- Amount sold
- $6.7M
- Minimum investment
- $521
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.9MraisedSep 2021 · 35 investors · BiotechnologyRule 506(b)
▶$9.9MraisedSep 2021 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin ChiarelliExecutive Officer, Director
- Scott ZingheimExecutive Officer, Director
- Nicky CaiazzaExecutive Officer, Director
- Spiros KambourakisExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $9.9M
- Minimum investment
- $5K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4.2MraisedJul 2019 · 21 investors · BiotechnologyRule 506(b)
▶$4.2MraisedJul 2019 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin ChiarelliExecutive Officer
- Offering amount
- $5M
- Amount sold
- $4.2M
- Sales commissions
- $72K
- Placement agents
- Paradigm Capital U.S., Inc.
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Cellino Bio8 shared keywordsCellineobio develops cell engineering and bioprocess technology platforms. The company serves biotech and pharmaceutical research and manufacturing customers.
CellFE5 shared keywordsCellFE develops microfluidics technology and instrumentation for cell therapy manufacturing, serving biotech researchers and clinical teams. The company's platform enables more efficient and accessible production of cell therapies for treatment applications.
Companies competing with Cellibre for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cellibre do?
- Cellibre engineers biological manufacturing by programming cells to produce industrial products through fermentation rather than traditional chemical synthesis. The company serves manufacturers seeking sustainable, cost-effective production of chemicals, materials, and other goods using cellular factories.
- Who founded Cellibre?
- Cellibre was founded by Ben Chiarelli in 2017.
- Who are Cellibre's investors?
- Cellibre's investors include Beresford Ventures, Dellin Investments, Delta Emerald Ventures, JourneyOne Ventures, Merida Capital Holdings, Flatiron Venture Partners.
- How much funding has Cellibre raised?
- Cellibre has disclosed $20.8M raised across 3 rounds.
- Where is Cellibre headquartered?
- Cellibre is headquartered in San Diego, US.